Pudilan (PDL) Treatment for COVID-19: Molecular Mechanism Analysis

68 co-targeted genes and proteins were analyzed to elucidate the molecular mechanism of the traditional Chinese medicine Pudilan (PDL) against COVID-19. The study, authored by Qi Kong from the Academy of Medical Sciences, used network pharmacology, protein-protein interaction analysis, and gene set enrichment. It suggests PDL may block viral entry via ACE2 and modulate immune responses involving proteins like IL-6, TNF, and CRP.

Use Cases

• Identifying potential drug targets for COVID-19 based on the 68 co-targeted genes/proteins.
• Validating network pharmacology predictions for traditional medicine using the TCMATCOV platform mentioned in the description.
• Analyzing protein-protein interaction networks for COVID-19 host-pathogen mechanisms based on the STRING analysis.
• Investigating cytokine storm inhibition pathways based on the described proteins like IL-6, TNF, and CCL5.

Strengths

• Analysis is based on 68 specific co-targeted genes/proteins identified for both PDL and COVID-19.
• Methodology integrates multiple established bioinformatics tools: SwissDock, STRING, WebGestalt, and TCMATCOV.
• The description details specific molecular pathways and proteins, such as ACE2, IL-6, and TNF.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• Last update date is unknown; freshness unverified.
• Data may reflect a specific methodological bias inherent to network pharmacology and the paperswithcode platform.

Provenance

Source

Academy of Medical Sciences

Collection Method

Network pharmacology analysis, molecular docking simulation, and gene set enrichment.